Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $20.50 Average PT from Brokerages

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been assigned an average recommendation of “Hold” from the nine analysts that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $20.50.

A number of research firms have recently commented on KROS. Leerink Partners dropped their price objective on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 4th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Wall Street Zen raised shares of Keros Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Wells Fargo & Company reduced their price objective on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. Finally, Zacks Research cut shares of Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 29th.

Keros Therapeutics Price Performance

Keros Therapeutics stock opened at $10.10 on Monday. Keros Therapeutics has a 12-month low of $9.69 and a 12-month high of $22.55. The stock has a market capitalization of $200.28 million, a PE ratio of -2.73 and a beta of 0.99. The firm has a 50 day simple moving average of $10.63 and a 200-day simple moving average of $12.10.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. On average, analysts forecast that Keros Therapeutics will post -5.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Julius Knowles sold 2,625 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the sale, the director directly owned 10,958 shares of the company’s stock, valued at $117,579.34. This represents a 19.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the transaction, the director owned 9,767 shares of the company’s stock, valued at $104,799.91. This trade represents a 21.18% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 8,425 shares of company stock worth $89,994. 12.60% of the stock is owned by insiders.

Institutional Trading of Keros Therapeutics

A number of hedge funds have recently bought and sold shares of KROS. ADAR1 Capital Management LLC acquired a new stake in shares of Keros Therapeutics during the second quarter valued at approximately $2,641,000. Hsbc Holdings PLC purchased a new position in Keros Therapeutics during the 2nd quarter worth approximately $761,000. PDT Partners LLC purchased a new position in Keros Therapeutics during the 2nd quarter worth approximately $122,000. Canada Pension Plan Investment Board acquired a new stake in Keros Therapeutics during the 2nd quarter valued at $247,000. Finally, Legal & General Group Plc acquired a new stake in Keros Therapeutics during the 2nd quarter valued at $90,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.